comparemela.com
  1. Home
  2. Live Updates
  3. Vogela Chan - Breaking News

Vogela Chan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Rivoceranib plus camrelizumab maintained a survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

Vogela chanJiangsu hengrui pharmaceuticals co ltdJiangsu hengrui medicine

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.